Literature DB >> 24323651

Biological Features of Human Bone Marrow Stromal Cells (hBMSC) Cultured with Animal Protein-Free Medium-Safety and Efficacy of Clinical Use for Neurotransplantation.

Hideo Shichinohe1, Satoshi Kuroda, Taku Sugiyama, Masaki Ito, Masahito Kawabori, Mitsufumi Nishio, Yukari Takeda, Takao Koike, Kiyohiro Houkin.   

Abstract

The donor cell culture in animal serum-free medium is quite important for the clinical application of cell transplantation therapy. This study was aimed to test the hypothesis that the human bone marrow stromal cells (hBMSC) expanded with fetal calf serum (FCS)-free, platelet lysate (PL)-containing medium retain their biological features favoring central nervous system regeneration. The hBMSC were cultured with 5% PL or 10% FCS. Their phenotypes were analyzed with flow cytometry, and their production of growth factors was quantified with enzyme-linked immunosorbent assay. Their capacity of neural differentiation was verified by immunocytochemistry. There was no significant difference in morphology and cell surface marker between the hBMSC-FCS and hBMSC-PL. Both of them were positive for CD44, CD90, CD105, and CD166 and were negative for CD34, CD45, and CD271. The production of human brain-derived neurotrophic factor, human hepatocyte growth factor, human β-nerve growth factor, and human platelet-derived growth factor-BB did not differ between the two groups, although the hBMSC-PL produced significantly more amount of TGF-β1 than the hBMSC-FCS. There was no significant difference in their in vitro differentiation into the neurons and astrocytes between the two groups. The hBMSC expanded with PL-containing medium retain their biological capacity of neural differentiation and neuroprotection. The PL may be a clinically valuable and safe substitute for FCS in expanding the hBMSC for cell therapy.

Entities:  

Year:  2011        PMID: 24323651     DOI: 10.1007/s12975-011-0088-y

Source DB:  PubMed          Journal:  Transl Stroke Res        ISSN: 1868-4483            Impact factor:   6.829


  50 in total

1.  Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy.

Authors:  P H Lee; J W Kim; O Y Bang; Y H Ahn; I S Joo; K Huh
Journal:  Clin Pharmacol Ther       Date:  2007-09-26       Impact factor: 6.875

2.  Bone marrow stromal cells promote neurite extension in organotypic spinal cord slice: significance for cell transplantation therapy.

Authors:  Hideo Shichinohe; Satoshi Kuroda; Sachiko Tsuji; Satoshi Yamaguchi; Shunsuke Yano; Jang-Bo Lee; Hiroyuki Kobayashi; Seiji Kikuchi; Kazutoshi Hida; Yoshinobu Iwasaki
Journal:  Neurorehabil Neural Repair       Date:  2008 Sep-Oct       Impact factor: 3.919

3.  Treatment of traumatic brain injury in female rats with intravenous administration of bone marrow stromal cells.

Authors:  A Mahmood; D Lu; L Wang; Y Li; M Lu; M Chopp
Journal:  Neurosurgery       Date:  2001-11       Impact factor: 4.654

4.  In vivo fluorescence tracking of bone marrow stromal cells transplanted into a pneumatic injury model of rat spinal cord.

Authors:  Shunsuke Yano; Satoshi Kuroda; Jang-Bo Lee; Hideo Shichinohe; Toshitaka Seki; Jun Ikeda; Goro Nishimura; Kazutoshi Hida; Mamoru Tamura; Yoshinobu Iwasaki
Journal:  J Neurotrauma       Date:  2005-08       Impact factor: 5.269

5.  Neural transplantation of human neuroteratocarcinoma (hNT) neurons into ischemic rats. A quantitative dose-response analysis of cell survival and behavioral recovery.

Authors:  S Saporta; C V Borlongan; P R Sanberg
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

6.  Adult bone marrow stromal cells differentiate into neural cells in vitro.

Authors:  J Sanchez-Ramos; S Song; F Cardozo-Pelaez; C Hazzi; T Stedeford; A Willing; T B Freeman; S Saporta; W Janssen; N Patel; D R Cooper; P R Sanberg
Journal:  Exp Neurol       Date:  2000-08       Impact factor: 5.330

7.  Stromal-derived factor-1 promotes the growth, survival, and development of human bone marrow stromal stem cells.

Authors:  Angela Kortesidis; Andrew Zannettino; Sandra Isenmann; Songtao Shi; Tsvee Lapidot; Stan Gronthos
Journal:  Blood       Date:  2005-01-27       Impact factor: 22.113

8.  Accelerated and safe expansion of human mesenchymal stromal cells in animal serum-free medium for transplantation and regenerative medicine.

Authors:  Claudia Lange; Figen Cakiroglu; Andrej-Nikolai Spiess; Heike Cappallo-Obermann; Judith Dierlamm; Axel R Zander
Journal:  J Cell Physiol       Date:  2007-10       Impact factor: 6.384

9.  Bone marrow stromal cells and bone marrow-derived mononuclear cells: which are suitable as cell source of transplantation for mice infarct brain?

Authors:  Hideo Shichinohe; Satoshi Kuroda; Katsuhiko Maruichi; Toshiya Osanai; Taku Sugiyama; Yasuhiro Chiba; Ayumi Yamaguchi; Yoshinobu Iwasaki
Journal:  Neuropathology       Date:  2009-09-07       Impact factor: 1.906

Review 10.  Bone marrow-derived mesenchymal stromal cells for the repair of central nervous system injury.

Authors:  A M Parr; C H Tator; A Keating
Journal:  Bone Marrow Transplant       Date:  2007-07-02       Impact factor: 5.483

View more
  13 in total

Review 1.  Stem cell therapy for cerebral ischemia: from basic science to clinical applications.

Authors:  Koji Abe; Toru Yamashita; Shunya Takizawa; Satoshi Kuroda; Hiroyuki Kinouchi; Nobutaka Kawahara
Journal:  J Cereb Blood Flow Metab       Date:  2012-01-18       Impact factor: 6.200

2.  Advancing biomaterials of human origin for tissue engineering.

Authors:  Fa-Ming Chen; Xiaohua Liu
Journal:  Prog Polym Sci       Date:  2015-03-28       Impact factor: 29.190

3.  Muse cells decrease the neuroinflammatory response by modulating the proportion of M1 and M2 microglia in vitro.

Authors:  Xin-Yao Yin; Chen-Chun Wang; Pan Du; Xue-Song Wang; Yi-Chi Lu; Yun-Wei Sun; Yue-Hui Sun; Yi-Man Hu; Xue Chen
Journal:  Neural Regen Res       Date:  2023-01       Impact factor: 6.058

4.  Platelet lysate and granulocyte-colony stimulating factor serve safe and accelerated expansion of human bone marrow stromal cells for stroke therapy.

Authors:  Tomohiro Yamauchi; Hisayasu Saito; Masaki Ito; Hideo Shichinohe; Kiyohiro Houkin; Satoshi Kuroda
Journal:  Transl Stroke Res       Date:  2014-07-26       Impact factor: 6.829

5.  Effects of bone marrow mesenchymal stem cells (BM-MSCs) on rat pial microvascular remodeling after transient middle cerebral artery occlusion.

Authors:  Dominga Lapi; Sabrina Vagnani; Daniela Sapio; Teresa Mastantuono; Francesca Boscia; Giuseppe Pignataro; Claudia Penna; Pasquale Pagliaro; Antonio Colantuoni
Journal:  Front Cell Neurosci       Date:  2015-08-25       Impact factor: 5.505

Review 6.  Current Opinion of Bone Marrow Stromal Cell Transplantation for Ischemic Stroke.

Authors:  Satoshi Kuroda
Journal:  Neurol Med Chir (Tokyo)       Date:  2016-03-15       Impact factor: 1.742

7.  Feasibility and Efficiency of Human Bone Marrow Stromal Cell Culture with Allogeneic Platelet Lysate-Supplementation for Cell Therapy against Stroke.

Authors:  Chengbo Tan; Hideo Shichinohe; Zifeng Wang; Shuji Hamauchi; Takeo Abumiya; Naoki Nakayama; Ken Kazumata; Tsuneo Ito; Kohsuke Kudo; Shigeru Takamoto; Kiyohiro Houkin
Journal:  Stem Cells Int       Date:  2016-10-20       Impact factor: 5.443

8.  Research on advanced intervention using novel bone marrOW stem cell (RAINBOW): a study protocol for a phase I, open-label, uncontrolled, dose-response trial of autologous bone marrow stromal cell transplantation in patients with acute ischemic stroke.

Authors:  Hideo Shichinohe; Masahito Kawabori; Hiroaki Iijima; Tuyoshi Teramoto; Takeo Abumiya; Naoki Nakayama; Ken Kazumata; Shunsuke Terasaka; Teruyo Arato; Kiyohiro Houkin
Journal:  BMC Neurol       Date:  2017-09-08       Impact factor: 2.474

Review 9.  Cell Therapy for Stroke: Review of Previous Clinical Trials and Introduction of Our New Trials.

Authors:  Hideo Shichinohe; Kiyohiro Houkin
Journal:  Neurol Med Chir (Tokyo)       Date:  2016-06-10       Impact factor: 1.742

10.  Increased microRNA-93-5p inhibits osteogenic differentiation by targeting bone morphogenetic protein-2.

Authors:  Ying Zhang; Qiu-Shi Wei; Wei-Bin Ding; Lei-Lei Zhang; Hui-Chao Wang; Ying-Jie Zhu; Wei He; Yu-Na Chai; You-Wen Liu
Journal:  PLoS One       Date:  2017-08-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.